These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31492448)

  • 1. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
    Feinberg D; Paul B; Kang Y
    Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent updates on CAR T clinical trials for multiple myeloma.
    Lin Q; Zhao J; Song Y; Liu D
    Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
    Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
    Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
    [No Abstract]   [Full Text] [Related]  

  • 6. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
    Jasiński M; Basak GW; Jedrzejczak WW
    Front Immunol; 2021; 12():632937. PubMed ID: 33717171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
    Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T-cell therapies for multiple myeloma.
    Mikkilineni L; Kochenderfer JN
    Blood; 2017 Dec; 130(24):2594-2602. PubMed ID: 28928126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
    Beauvais D; Danhof S; Hayden PJ; Einsele H; Yakoub-Agha I
    Curr Opin Oncol; 2020 Sep; 32(5):418-426. PubMed ID: 32740095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cell therapy: is it prime time in myeloma?
    Sidana S; Shah N
    Blood Adv; 2019 Nov; 3(21):3473-3480. PubMed ID: 31714964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
    Cohen AD
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
    [No Abstract]   [Full Text] [Related]  

  • 16. CAR T and CAR NK cells in multiple myeloma: Expanding the targets.
    Shah UA; Mailankody S
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101141. PubMed ID: 32139020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T Therapy in Relapsed Refractory Multiple Myeloma.
    Ding H; Wu Y
    Curr Med Chem; 2024; 31(27):4362-4382. PubMed ID: 37779413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.